Announcing Launch@LabShares

We encourage start-up biotech companies to enter the Business Plan Competition run by LabShares/Newton – sponsored in part by Faber Daeufer & Itrato

Winner receives a free one-year membership, including shared office and lab space for one scientist as well as all resources and amenities at LabShares/Newton, an extraordinary shared office and laboratory incubator for emerging biotechnology and life science companies.
Applications must be received by LabShares by April 15.  See https://www.labshares.com/launch.

It may be good science, but is it a good deal?

Explore our services
Why In-House Experience Matters
X
Clinical Trial Agreements
Commercial Agreements
Industry Collaborations
Private Financing
Strategic Transactions
University Collaborations
It may be good science, but is it a good deal?It may be good science, but is it a good deal?

When we look at a term sheet, we see a single piece of an overall business strategy.

Our goal is to design a transaction, not just to monetize IP, but also to drive the growth of your entire business. We can help you in the following ways:

Start-up

Start-up

License core technologies and obtain venture financing

Learn More
Clinical Study

clinical study

Launch and complete a complex clinical trial

Learn More
Partner

partner

Structure a research or product development collaboration

Learn More
Exit

exit

Close a strategic transaction for growth or exit

Learn More
Start-up

Start-up

License core technologies and obtain venture financing

Learn More
Clinical Study

clinical study

Launch and complete a complex clinical trial

Learn More
Partner

partner

Structure a research or product development collaboration

Learn More
Exit

exit

Close a strategic transaction for growth or exit

Learn More

Our lawyers started out on the industry side.

We came from pharma, life sciences and emerging technologies.
meet our professionalsWhy In-House Experience Matters
Our lawyers started out on the industry side.Our lawyers started out on the industry side.

We have deep experience.

We have worked with over 1000 companies, investors and research institutions in the life sciences and high-tech fields.
SEE OUR CLIENTS
LifeMine Therapeutics, Inc. Logo
LifeMine Therapeutics, Inc.
Series A Financing

Equity Financing by Foresite Capital, Google Ventures, Arch Ventures, Boyu Capital, Blue Pool Capital, Merck Ventures, and Alexandria Venture Investments

Press Release
AuthAir Logo and LogMeIn Logo
AuthAir, Inc.— LogMeIn, Inc.
Private Company Sale

Sale of AuthAir, Inc., a portfolio company of .406 Ventures providing proximity-based security and wireless authentication solutions with real-time analytics to assist healthcare providers with compliance, regulation and business intelligence, to LogMeIn

Press Release
ImmunoGen Logo and Debiopharm International Logo
ImmunoGen, Inc. - Debiopharm International SA
Sale of Development Program

Sale of phase II antibody-drug conjugate assets from ImmunoGen for up to $55 million

Press Release
Lysosomal Therapeutics, Inc. Logo and Allergan plc Logo
Lysosomal Therapeutics, Inc.— Allergan plc
Exclusive Option to Aquire Company

Sale to Allergan of exclusive option to acquire LTI following completion of phase IB Clinical Trial

Press Release
Kite Pharma, Inc. Logo and Cell Design Labs Logo
Kite Pharma, Inc.—Cell Design Labs
Strategic Research Collaboration Agreement

Strategic Research Collaboration for CAR T-cell Immunotherapeutics

Press Release
Partners in Health Logo
Partners in Health
Clinical Trial

CRO and Site Agreements for Phase 4 Clinical Study of Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

See Study
BeiGene Logo
BeiGene, Ltd.
Clinical Trial

CRO and Site Agreements for Global Phase 3 Multicenter Study BGB-3111 and Ibrutinib

Press Release
Yumanity Therapeutics Logo and New York Stem Cell Foundation Logo
Yumanity Therapeutics—New York Stem Cell Foundation
Discovery Collaboration

Discovery Collaboration Focused on Generation of Stem Cell Lines to Enable Development of Novel Therapeutics for Neurodegenerative Diseases

Press Release
CAP Logo and Henry Schein Logo
Custom Automated Prosthetics - Henry Schein, Inc.
Private Company Sale

Sale of Custom Automated Prosthetics (digital dental laboratory supply company) to Henry Schein

Press Release
Paratek Pharmaceuticals, Inc. Logo
Paratek Pharmaceuticals, Inc.
Clinical Trial

CRO and Site Agreements for Multiple Global Phase 3 Multi-Center Studies of Omadacyline Intravenous/Oral (PO)

See Study
Magenta Therapeutics Logo and Harvard University Logo
Magenta Therapeutics — Harvard University
License Agreement

Launch of New Venture Focused on Stem Cell Transplants to Treat Early-Stage Cancers and Autoimmune Diseases, Including Exclusive License from Harvard University

Press Release
WAVE Life Sciences Ltd. Logo and Pfizer Inc. Logo
WAVE Life Sciences Ltd.— Pfizer Inc.
Strategic Research Collaboration Agreement

Strategic Research Collaboration to Develop Treatments for Metabolic Diseases Utilizing Proprietary Antisense and RNAi Technologies (including $40 million in upfront payments, up to $871 million in milestone payments, and royalties)

Press Release
Phenex Pharmaceuticals Logo and Gilead Sciences Logo
Phenex Pharmaceuticals – Gilead Sciences
Program Sale

Sale of Phenex’s FXR program for the treatment of non-alcoholic steatohepatitis (NASH) and other liver diseases

Press Release
Unum Therapeutics, Inc. Logo and National University of Singapore Logo
Unum Therapeutics, Inc. - National University of Singapore
Exclusive License Agreement

Exclusive license agreement with National University of Singapore for the in-license of core platform technology for T-cell based therapeutics

Press Release
Annapurna Therapeutics Logo
Annapurna Therapeutics - Weill Cornell Medical
Exclusive License Agreement

Gene Therapy Alliance with Weill Cornell Medical through a series of 3 exclusive license agreements and a services agreement for research, development and commercialization of multiple AAV-based gene therapy indications

Press Release
LifeMine Therapeutics, Inc. Logo
LifeMine Therapeutics, Inc.
Series A Financing

Equity Financing by Foresite Capital, Google Ventures, Arch Ventures, Boyu Capital, Blue Pool Capital, Merck Ventures, and Alexandria Venture Investments

Press Release
AuthAir Logo and LogMeIn Logo
AuthAir, Inc.— LogMeIn, Inc.
Private Company Sale

Sale of AuthAir, Inc., a portfolio company of .406 Ventures providing proximity-based security and wireless authentication solutions with real-time analytics to assist healthcare providers with compliance, regulation and business intelligence, to LogMeIn

Press Release
ImmunoGen Logo and Debiopharm International Logo
ImmunoGen, Inc. - Debiopharm International SA
Sale of Development Program

Sale of phase II antibody-drug conjugate assets from ImmunoGen for up to $55 million

Press Release
Lysosomal Therapeutics, Inc. Logo and Allergan plc Logo
Lysosomal Therapeutics, Inc.— Allergan plc
Exclusive Option to Aquire Company

Sale to Allergan of exclusive option to acquire LTI following completion of phase IB Clinical Trial

Press Release
Kite Pharma, Inc. Logo and Cell Design Labs Logo
Kite Pharma, Inc.—Cell Design Labs
Strategic Research Collaboration Agreement

Strategic Research Collaboration for CAR T-cell Immunotherapeutics

Press Release
Partners in Health Logo
Partners in Health
Clinical Trial

CRO and Site Agreements for Phase 4 Clinical Study of Hepatitis C Antiviral Therapy in Rwanda for Elsewhere in the Developing World

See Study
© Faber Daeufer & Itrato PC. All Rights Reserved.
781 795 4700 main
|
Disclaimer
|
Attorney Advertising